|
1
|
Walker PGT, Whittaker C, Watson OJ,
Baguelin M, Winskill P, Hamlet A, Djafaara BA, Cucunubá Z, Olivera
Mesa D, Green W, et al: The impact of COVID-19 and strategies for
mitigation and suppression in low- and middle-income countries.
Science. 369:413–422. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khan S, Siddique R, Ali A, Bai Q, Li Z, Li
H, Shereen MA, Xue M and Nabi G: The spread of novel coronavirus
has created an alarming situation worldwide. J Infect Public
Health. 13:469–471. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Killerby ME, Biggs HM, Midgley CM, Gerber
SI and Watson JT: Middle east respiratory syndrome coronavirus
transmission. Emerg Infect Dis. 26:191–198. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Watson OJ, Barnsley G, Toor J, Hogan AB,
Winskill P and Ghani AC: Global impact of the first year of
COVID-19 vaccination: A mathematical modelling study. Lancet Infect
Dis. 22:1293–1302. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tulimilli SV, Dallavalasa S, Basavaraju
CG, Kumar Rao V, Chikkahonnaiah P, Madhunapantula SV and Veeranna
RP: Variants of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) and vaccine effectiveness. Vaccines (Basel).
10:17512022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Villamagna AH, Gore SJ, Lewis JS and
Doggett JS: The need for antiviral drugs for pandemic coronaviruses
from a global health perspective. Front Med (Lausanne).
7:5965872020. View Article : Google Scholar
|
|
7
|
Takashita E, Kinoshita N, Yamayoshi S,
Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P,
Watanabe S, Maeda K, et al: Efficacy of antiviral agents against
the SARS-CoV-2 omicron subvariant BA.2. N Engl J Med.
386:1475–1477. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kumari M, Lu RM, Li MC, Huang JL, Hsu FF,
Ko SH, Ke FY, Su SC, Liang KH, Yuan JP, et al: A critical overview
of current progress for COVID-19: Development of vaccines,
antiviral drugs, and therapeutic antibodies. J Biomed Sci.
29:682022. View Article : Google Scholar
|
|
9
|
Zhu C, Lee JY, Woo JZ, Xu L, Nguyenla X,
Yamashiro LH, Ji F, Biering SB, Van Dis E, Gonzalez F, et al: An
intranasal ASO therapeutic targeting SARS-CoV-2. Nat Commun.
13:45032022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mondal S, Quintili AL, Karamchandani K and
Bose S: Thromboembolic disease in COVID-19 patients: A brief
narrative review. J Intensive Care. 8:702020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zong X, Gu Y, Yu H, Li Z and Wang Y:
Thrombocytopenia is associated with COVID-19 severity and outcome:
An updated meta-analysis of 5637 patients with multiple outcomes.
Lab Med. 52:10–15. 2021. View Article : Google Scholar
|
|
12
|
Smilowitz NR, Kunichoff D, Garshick M,
Shah B, Pillinger M, Hochman JS and Berger JS: C-reactive protein
and clinical outcomes in patients with COVID-19. Eur Heart J.
42:2270–2279. 2021. View Article : Google Scholar
|
|
13
|
Santa Cruz A, Mendes-Frias A, Oliveira AI,
Dias L, Matos AR, Carvalho A, Capela C, Pedrosa J, Castro AG and
Silvestre R: Interleukin-6 is a biomarker for the development of
fatal severe acute respiratory syndrome coronavirus 2 pneumonia.
Front Immunol. 12:6134222021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu B, Huang S and Yin L: The cytokine
storm and COVID-19. J Med Virol. 93:250–256. 2021. View Article : Google Scholar
|
|
15
|
Iwasaki M, Saito J, Zhao H, Sakamoto A,
Hirota K and Ma D: Inflammation triggered by SARS-CoV-2 and ACE2
augment drives multiple organ failure of severe COVID-19: Molecular
mechanisms and implications. Inflammation. 44:13–34. 2021.
View Article : Google Scholar
|
|
16
|
Yang J, Petitjean SJL, Koehler M, Zhang Q,
Dumitru AC, Chen W, Derclaye S, Vincent SP, Soumillion P and
Alsteens D: Molecular interaction and inhibition of SARS-CoV-2
binding to the ACE2 receptor. Nat Commun. 11:45412020. View Article : Google Scholar :
|
|
17
|
Song P, Li W, Xie J, Hou Y and You C:
Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 509:280–287.
2020. View Article : Google Scholar :
|
|
18
|
Hazeldine J and Lord JM: Neutrophils and
COVID-19: Active participants and rational therapeutic targets.
Front Immunol. 12:6801342021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Veenith T, Martin H, Le Breuilly M,
Whitehouse T, Gao-Smith F, Duggal N, Lord JM, Mian R, Sarphie D and
Moss P: High generation of reactive oxygen species from neutrophils
in patients with severe COVID-19. Sci Rep. 12:104842022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sefik E, Qu R, Junqueira C, Kaffe E, Mirza
H, Zhao J, Brewer JR, Han A, Steach HR, Israelow B, et al:
Inflammasome activation in infected macrophages drives COVID-19
pathology. Nature. 606:585–593. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moss P: The T cell immune response against
SARS-CoV-2. Nat Immunol. 23:186–193. 2022. View Article : Google Scholar
|
|
22
|
Mohammed RN, Tamjidifar R, Rahman HS,
Adili A, Ghoreishizadeh S, Saeedi H, Thangavelu L, Shomali N,
Aslaminabad R, Marofi F, et al: A comprehensive review about immune
responses and exhaustion during coronavirus disease (COVID-19).
Cell Commun Signal. 20:792022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Majidpoor J and Mortezaee K: Interleukin-6
in SARS-CoV-2 induced disease: Interactions and therapeutic
applications. Biomed Pharmacother. 145:1124192022. View Article : Google Scholar
|
|
24
|
Zizzo G, Tamburello A, Castelnovo L, Laria
A, Mumoli N, Faggioli PM, Stefani I and Mazzone A: Immunotherapy of
COVID-19: Inside and beyond IL-6 signalling. Front Immunol.
13:7953152022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khan S, Shafiei MS, Longoria C, Schoggins
JW, Savani RC and Zaki H: SARS-CoV-2 spike protein induces
inflammation via TLR2-dependent activation of the NF-κB pathway.
Elife. 10:e685632021. View Article : Google Scholar
|
|
26
|
Matsuyama T, Kubli SP, Yoshinaga SK,
Pfeffer K and Mak TW: An aberrant STAT pathway is central to
COVID-19. Cell Death Differ. 27:3209–3225. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaiser AE, Baniasadi M, Giansiracusa D,
Giansiracusa M, Garcia M, Fryda Z, Wong TL and Bishayee A:
Sulforaphane: A broccoli bioactive phytocompound with cancer
preventive potential. Cancers (Basel). 13:47962021. View Article : Google Scholar
|
|
28
|
Barba FJ, Nikmaram N, Roohinejad S, Khelfa
A, Zhu Z and Koubaa M: Bioavailability of glucosinolates and their
breakdown products: Impact of processing. Front Nutr. 3:242016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Narbad A and Rossiter JT: Gut
glucosinolate metabolism and isothiocyanate production. Mol Nutr
Food Res. 62:e17009912018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lenzi M, Fimognari C and Hrelia P:
Sulforaphane as a promising molecule for fighting cancer. Cancer
Treat Res. 159:207–223. 2014. View Article : Google Scholar
|
|
31
|
Kubo E, Chhunchha B, Singh P, Sasaki H and
Singh DP: Sulforaphane reactivates cellular antioxidant defense by
inducing Nrf2/ARE/Prdx6 activity during aging and oxidative stress.
Sci Rep. 7:141302017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Haristoy X, Angioi-Duprez K, Duprez A and
Lozniewski A: Efficacy of sulforaphane in eradicating Helicobacter
pylori in human gastric xenografts implanted in nude mice.
Antimicrob Agents Chemother. 47:3982–3984. 2003. View Article : Google Scholar
|
|
33
|
Schepici G, Bramanti P and Mazzon E:
Efficacy of sulforaphane in neurodegenerative diseases. Int J Mol
Sci. 21:86372020. View Article : Google Scholar :
|
|
34
|
Li YP, Wang SL, Liu B, Tang L, Kuang RR,
Wang XB, Zhao C, Song XD, Cao XM, Wu X, et al: Sulforaphane
prevents rat cardiomyocytes from hypoxia/reoxygenation injury in
vitro via activating SIRT1 and subsequently inhibiting ER stress.
Acta Pharmacol Sin. 37:344–353. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qi T, Xu F, Yan X, Li S and Li H:
Sulforaphane exerts anti-inflammatory effects against
lipopolysaccharide-induced acute lung injury in mice through the
Nrf2/ARE pathway. Int J Mol Med. 37:182–188. 2016. View Article : Google Scholar
|
|
36
|
Folkard DL, Marlow G, Mithen RF and
Ferguson LR: Effect of sulforaphane on NOD2 via NF-κB: Implications
for Crohn's disease. J Inflamm (Lond). 12:62015. View Article : Google Scholar
|
|
37
|
Negi G, Kumar A and Sharma SS: Nrf2 and
NF-κB modulation by sulforaphane counteracts multiple
manifestations of diabetic neuropathy in rats and high
glucose-induced changes. Curr Neurovasc Res. 8:294–304. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu C, Shen G, Chen C, Gélinas C and Kong
ANT: Suppression of NF-kappaB and NF-kappaB-regulated gene
expression by sulforaphane and PEITC through IkappaBalpha, IKK
pathway in human prostate cancer PC-3 cells. Oncogene.
24:4486–4495. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu T, Zhang L, Joo D and Sun SC: NF-κB
signaling in inflammation. Signal Transduct Target Ther.
2:170232017. View Article : Google Scholar
|
|
40
|
Libermann TA and Baltimore D: Activation
of interleukin-6 gene expression through the NF-kappa B
transcription factor. Mol Cell Biol. 10:2327–2334. 1990.PubMed/NCBI
|
|
41
|
McFarland BC, Hong SW, Rajbhandari R,
Twitty GB Jr, Gray GK, Yu H, Benveniste EN and Nozell SE:
NF-κB-induced IL-6 ensures STAT3 activation and tumor
aggressiveness in glioblastoma. PLoS One. 8:e787282013. View Article : Google Scholar
|
|
42
|
Elliott CL, Allport VC, Loudon JA, Wu GD
and Bennett PR: Nuclear factor-kappa B is essential for
up-regulation of interleukin-8 expression in human amnion and
cervical epithelial cells. Mol Hum Reprod. 7:787–790. 2001.
View Article : Google Scholar
|
|
43
|
Fahey JW and Kensler TW: The challenges of
designing and implementing clinical trials with broccoli sprouts…
and turning evidence into public health action. Front Nutr.
8:6487882021. View Article : Google Scholar
|
|
44
|
Yagishita Y, Fahey JW, Dinkova-Kostova AT
and Kensler TW: Broccoli or sulforaphane: Is it the source or dose
that matters? Molecules. 24:35932019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yagishita Y, Gatbonton-Schwager TN,
McCallum ML and Kensler TW: Current landscape of NRF2 biomarkers in
clinical trials. Antioxidants (Basel). 9:7162020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zimmerman AW, Singh K, Connors SL, Liu H,
Panjwani AA, Lee LC, Diggins E, Foley A, Melnyk S, Singh IN, et al:
Randomized controlled trial of sulforaphane and metabolite
discovery in children with autism spectrum disorder. Mol Autism.
12:382021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gasparello J, D'Aversa E, Papi C, Gambari
L, Grigolo B, Borgatti M, Finotti A and Gambari R: Sulforaphane
inhibits the expression of interleukin-6 and interleukin-8 induced
in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2
spike protein. Phytomedicine. 87:1535832021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ordonez AA, Bullen CK, Villabona-Rueda AF,
Thompson EA, Turner ML, Merino VF, Yan Y, Kim J, Davis SL, Komm O,
et al: Sulforaphane exhibits antiviral activity against pandemic
SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in
mice. Commun Biol. 5:2422022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bortolotti D, Gentili V, Rizzo S, Schiuma
G, Beltrami S, Strazzabosco G, Fernandez M, Caccuri F, Caruso A and
Rizzo R: TLR3 and TLR7 RNA sensor activation during SARS-CoV-2
infection. Microorganisms. 9:18202021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Papi C, Gasparello J, Zurlo M, Manicardi
A, Corradini R, Cabrini G, Gambari R and Finotti A: Combined
treatment of bronchial epithelial Calu-3 cells with peptide nucleic
acids targeting miR-145-5p and miR-101-3p: Synergistic enhancement
of the expression of the cystic fibrosis transmembrane conductance
regulator (CFTR) gene. Int J Mol Sci. 23:93482022. View Article : Google Scholar
|
|
51
|
Gasparello J, Papi C, Zurlo M, Gambari L,
Rozzi A, Manicardi A, Corradini R, Gambari R and Finotti A:
Treatment of human glioblastoma U251 cells with sulforaphane and a
peptide nucleic acid (PNA) targeting miR-15b-5p: Synergistic
effects on induction of apoptosis. Molecules. 27:12992022.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Heiss E, Herhaus C, Klimo K, Bartsch H and
Gerhäuser C: Nuclear factor kappa B is a molecular target for
sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem.
276:32008–32015. 2001. View Article : Google Scholar
|
|
53
|
Caruso A, Caccuri F, Bugatti A, Zani A,
Vanoni M, Bonfanti P, Cazzaniga ME, Perno CF, Messa C and
Alberghina L: Methotrexate inhibits SARS-CoV-2 virus replication
'in vitro'. J Med Virol. 93:1780–1785. 2021. View Article : Google Scholar
|
|
54
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
55
|
Van Der Spoel D, Lindahl E, Hess B,
Groenhof G, Mark AE and Berendsen HJC: GROMACS: Fast, flexible, and
free. Comput Chem. 26:1701–1718. 2005. View Article : Google Scholar
|
|
56
|
Pronk S, Páll S, Schulz R, Larsson P,
Bjelkmar P, Apostolov R, Shirts MR, Smith JC, Kasson PM, van der
Spoel D, et al: GROMACS 4.5: A high-throughput and highly parallel
open source molecular simulation toolkit. Bioinformatics.
29:845–854. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Marrink SJ, Risselada HJ, Yefimov S,
Tieleman DP and de Vries AH: The MARTINI force field: Coarse
grained model for biomolecular simulations. J Phys Chem B.
111:7812–7824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Bereau T and Kremer K: Automated
parametrization of the coarse-grained Martini force field for small
organic molecules. J Chem Theory Comput. 11:2783–2791. 2015.
View Article : Google Scholar
|
|
59
|
Lamprakis C, Andreadelis I, Manchester J,
Velez-Vega C, Duca JS and Cournia Z: Evaluating the efficiency of
the Martini force field to study protein dimerization in aqueous
and membrane environments. J Chem Theory Comput. 17:3088–3102.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Souza PCT, Thallmair S, Conflitti P,
Ramírez-Palacios C, Alessandri R, Raniolo S, Limongelli V and
Marrink SJ: Protein-ligand binding with the coarse-grained Martini
model. Nat Commun. 11:37142020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Honorato RV, Roel-Touris J and Bonvin
AMJJ: MARTINI-based protein-DNA coarse-grained HADDOCKing. Front
Mol Biosci. 6:1022019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Periole X, Cavalli M, Marrink SJ and
Ceruso MA: Combining an elastic network with a coarse-grained
molecular force field: Structure, dynamics, and intermolecular
recognition. J Chem Theory Comput. 5:2531–2543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang X, Wu K, Wang D, Yue X, Song D, Zhu
Y and Wu J: Nucleocapsid protein of SARS-CoV activates
interleukin-6 expression through cellular transcription factor
NF-kappaB. Virology. 365:324–335. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
du Preez HN, Aldous C, Kruger HG and
Johnson L: N-Acetylcysteine and other sulfur-donors as a
preventative and adjunct therapy for COVID-19. Adv Pharmacol Pharm
Sci. 2022:45554902022.PubMed/NCBI
|
|
65
|
Zinovkin RA and Grebenchikov OA:
Transcription factor Nrf2 as a potential therapeutic target for
prevention of cytokine storm in COVID-19 patients. Biochemistry
(Mosc). 85:833–837. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cuadrado A, Pajares M, Benito C,
Jiménez-Villegas J, Escoll M, Fernández-Ginés R, Garcia Yagüe AJ,
Lastra D, Manda G, Rojo AI and Dinkova-Kostova AT: Can activation
of NRF2 Be a strategy against COVID-19? Trends Pharmacol Sci.
41:598–610. 2020. View Article : Google Scholar :
|
|
67
|
Kow CS, Ramachandram DS and Hasan SS: Use
of sulforaphane in COVID-19: Clinical trials are needed. Mol
Immunol. 145:78–79. 2022. View Article : Google Scholar :
|
